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CVD accounted for 27 % of all deaths in the UK in 2014, and was responsible for 1·7 million
hospital admissions in 2013/2014. This condition becomes increasingly prevalent with age,
affecting 34·1 and 29·8 % of males and females over 75 years of age respectively in 2011.
The dysregulation of cholesterol metabolism with age, often observed as a rise in LDL-chol-
esterol, has been associated with the pathogenesis of CVD. To compound this problem, it is
estimated by 2050, 22 % of the world’s population will be over 60 years of age, in culmin-
ation with a growing resistance and intolerance to pre-existing cholesterol regulating drugs
such as statins. Therefore, it is apparent research into additional therapies for hypercholes-
terolaemia and CVD prevention is a growing necessity. However, it is also imperative to rec-
ognise this complex biological system cannot be studied using a reductionist approach;
rather its biological uniqueness necessitates a more integrated methodology, such as that
offered by systems biology. In this review, we ﬁrstly discuss cholesterol metabolism and
how it is affected by diet and the ageing process. Next, we describe therapeutic strategies
for hypercholesterolaemia, and ﬁnally how the systems biology paradigm can be utilised
to investigate how ageing interacts with complex systems such as cholesterol metabolism.
We conclude by emphasising the need for nutritionists to work in parallel with the systems
biology community, to develop novel approaches to studying cholesterol metabolism and its
interaction with ageing.
Cholesterol: Ageing: Systems biology: Computational modelling
Life expectancy has increased dramatically (Fig. 1). In
the UK, males and females born in 1982, had a life
expectancy of 71·1 and 77·0 years, respectively, while
the projected values for 2082 are 89·7 and 92·6 years(1).
Thus, we are witnessing a staggering demographic shift
in favour of older people (Fig. 2). For instance, it has
been estimated the percentage of individuals in the UK
over 60 years of age will double to 22 % by 2050, when
compared to 2000(2). Remaining disease free is a signiﬁ-
cant challenge faced by older people, as the prevalence
of many conditions increases with age (Fig. 3). Of the
diseases associated with advancing age, CVD is the
leading cause of morbidity in individuals over 60 years
of age(3). The dysregulation of cholesterol metabolism
is intimately associated with the pathogenesis of
CVD(4), and age-related alterations in the metabolism
of cholesterol are implicated in the disturbance of this
system(5). These include, a decrease in LDL-cholesterol
clearance; a potential increase in cholesterol absorption;
a decrease in bile acid synthesis; a decrease in bacterial
bile acid modiﬁcation(6–8). It is likely that these altera-
tions play a role in the accumulation of LDL-cholesterol
and disease pathogenesis. The accumulation of plasma
cholesterol can also be moderated by diet, while
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pharmaceutical and pre- and probiotic administration
have largely been associated with reduced LDL-
cholesterol levels and CVD risk(9–13).
Traditionally, when nutritionists have investigated
complex metabolic pathways, such as cholesterol metab-
olism, they have utilised conventional wet laboratory
techniques. However, studying cholesterol metabolism
and its interaction with both diet and ageing using con-
ventional approaches is challenging, due to the integrated
nature of this system, and the time scales involved in
studying the effects of the ageing process. Traditional
in vivo or in vitro techniques can also be limited when
testing a hypothesis, as such approaches can be
resource-intensive, expensive, impractical and potentially
unethical(14). Thus, utilisation of the systems biology
approach is becoming an increasingly important tool in
nutrition-based research, as systems biology overcomes
a number of the challenges outlined earlier, but more
importantly, facilitates the integration of data generated
from a diverse range of sources(14), leading to an
improved understanding of how cellular dynamics inﬂu-
ence the behaviour of tissues and ultimately the health of
whole-organ systems(15). Thus, the systems biology
approach seeks to understand complex biological systems
by studying them in a more holistic manner, in contrast
to the reductionist approach regularly adopted in
human nutrition. At the core of the systems biology
approach is computational modelling. Computational
modelling is an abstract process that is used to represent
the dynamics of a biological system in a precise manner
using mathematics. The steps involved in building a com-
putational model are outlined in Fig. 4. Computational
models are now used to model a diverse range of complex
nutrient centred pathways including cholesterol metabol-
ism for a number of reasons. Firstly, computational
models are capable of providing quantitative data on
the interaction of molecular components(16). Secondly,
nutrient-based interactions are inherently complex and
often non-linear in nature(17–19), and can involve complex
feedback and feedforward loops(20–22). Thus, it is chal-
lenging and even unfeasible to reason about these by
human intuition alone. Computational modelling offers
an alternative means of handling this complexity; thus,
utilisation of computational modelling alongside the
experimental work provides a means of representing
the dynamics of complex biological systems. Models
can be used to simulate intrinsic perturbations, such as
those associated with ageing and extrinsic perturbations,
such as diet. Output from the model provides an over-
view of how these changes impact the dynamics of the
system, and the implications this has for healthspan. In
this review, we present an overview of cholesterol metab-
olism and discuss how ageing impacts its regulatory
mechanisms. We also discuss how diet inﬂuences choles-
terol metabolism, and how the dysregulation of this sys-
tem inﬂuences heath. Next, we discuss therapeutic
strategies for the treatment of hypercholesterolaemia,
namely dietary, pharmacological and probiotic interven-
tion. Finally, we describe how we are using the systems
biology framework to investigate cholesterol metabolism
and the impact ageing has on it. Speciﬁcally, there is a
focus on how we have used computational modelling
and how we are exploring this approach with simulated
digestive tracks.
Overview of cholesterol metabolism
Cholesterol plays a vital role in the body as a component
of cell membranes, and precursor to steroid hormones
and bile acids. Whole-body cholesterol metabolism is
encapsulated by cholesterol ingestion, absorption, excre-
tion and synthesis. These factors interact in a coordi-
nated fashion to regulate whole-body cholesterol
balance, with subtle changes to individual components
inﬂuencing the behaviour of the others, so that choles-
terol balance is maintained. In the next sections, we
will outline in detail the complexities of cholesterol
metabolism and how ageing interacts with it, thus
emphasising the need for a systems biology approach
when investigating it.
Cholesterol ingestion and absorption
In the UK, the average daily intake of cholesterol is 304
and 213 mg for males and females, respectively(23), 10–
15 % of which is in the esteriﬁed form(24). In the small
intestine, esteriﬁed cholesterol is hydrolysed to form
free cholesterol, which is more readily incorporated
into bile acid micelles, which facilitate the absorption
of cholesterol via Niemann–Pick C1-like 1 protein
(NPC1L1)(25,26). Additionally, phytosterols can also be
absorbed via NPC1L1(27). Intestinal absorption of chol-
esterol and phytosterols can be limited by heterodimer
ATP-binding cassette (ABC) G5/G8, which efﬂuxes
these sterols back to the intestinal lumen(28). Acyl CoA:
cholesterol acyltransferase 2 esteriﬁes internalised choles-
terol, which is then incorporated into a nascent chylo-
micron via microsomal TAG transfer protein(29,30). The
nascent chylomicron then exits the enterocyte by exocyt-
osis into the lymphatic system before entering the blood
stream(31). The nascent chylomicron is converted to a
mature chylomicron upon acquisition of apo C-II and
E from HDL. Apo C-II activates lipoprotein lipase on
the capillary endothelium of adipose or muscle tissue,
Fig. 1. UK life expectancy by year of birth. Data from Clio-
Infra(132).
A. E. Morgan et al.2
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which in turn catalyses the hydrolysis of TAG(32,33). Apo
C-II is then returned to HDL, and hepatic LDL recep-
tors (LDLr) and LDLr-related protein recognise apo
B-48 and E, initiating the absorption of the chylomicron
remnants(34).
Cholesterol synthesis
Cholesterol is synthesised endogenously in all nucleated
cells in the body from acetyl CoA(35). Renfurm et al.(36)
observed endogenous cholesterol was synthesised at a
rate of 9·8 (SD 6·2) mg/kg per d in healthy adults with a
mean age of 32 years and mean weight of 64 kg. This
equates to 627·2 mg/d synthesised cholesterol, a similar
value to the 710 mg/d observed by Jones and
Schoeller(37). Interestingly, cholesterol consumption can
inﬂuence the synthesis of endogenous cholesterol; an
increase from 173 to 781 mg/d dietary cholesterol has
been observed to decrease the rate of sterol synthesis by
34 %(38).
Cholesterol synthesis commences when acetoacetyl
CoA thiolase catalyses the interconversion of acetyl CoA
and acetoacetyl CoA. One molecule acetyl CoA and
one molecule acetoacetyl CoA undergo a condensation
reaction by 3-hydroxy-3-methylglutaryl (HMG) CoA
synthase to form a molecule of HMG CoA. HMG
CoA reductase, with the addition of two NADPH mole-
cules, and then catalyse the conversion of HMG CoA to
mevalonate. As the rate-limiting enzyme of cholesterol
biosynthesis, HMG CoA reductase is the therapeutic
target of statins, for the treatment of hypercholesterol-
aemia, and the prevention of atherosclerosis(39).
Phosphorylation of mevalonate by the enzyme mevalo-
nate kinase forms mevalonate-5P, which undergoes fur-
ther phosphorylation to form mevalonate-5PP via the
enzyme phosphomevalonate kinase. Decarboxylation
and dehydration by mevalonate-5PP decarboxylase create
isopentenyl-PP and thus its isoform dimethylallyl-PP via
isopentenyl diphosphate delta isomerase. Farnesyl diphos-
phate synthase initiates the condensation of dimethylallyl-
PP with one molecule of isopentenyl-PP and NADPH to
create geranyl-PP. Further condensation and the addition
of another molecule of isopentenyl-PP and NADPH
create farnesyl-PP. Condensation of two farnesyl-PP
molecules by squalene synthase and NADPH forms
squalene, which is then converted to squalene epoxide
by squalene epoxidase, NADPH, and O2, before under-
going cyclisation by oxidosqualene cyclase to form
lanosterol(40). A series of reactions, including the branch-
ing of 7-dehydrodesmosterol to either desmosterol or
7-dehydrocholesterol, both of which can then be con-
verted to the end product cholesterol via the enzymes
24-dehydrocholesterol reductase and 7-dehydrocholes-
terol reductase concludes the de novo synthesis of
cholesterol(41,42).
Lipoprotein dynamics and reverse cholesterol transport
VLDL-cholesterol is formed from the hepatic pool of
cholesterol to transport endogenously synthesised TAG
to the tissues(43). Partial hydrolysis of VLDL by lipopro-
tein lipase forms intermediate density lipoprotein, with
subsequent hydrolysis of intermediate-density lipoprotein
Fig. 2. (Colour online) UK population by age and sex in 1982 and 2012. Data from United Nations
Statistics Division(133).
Fig. 3. (Colour online) UK causes of death by age. Data from
British Heart Foundation(134).
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by hepatic lipase forming LDL, which acts to deliver
cholesterol to the peripheral tissue(43). VLDL-cholesterol,
intermediate-density lipoprotein-cholesterol and LDL-
cholesterol can be removed from the circulation by hep-
atic LDLr, while LDL-cholesterol can also be absorbed
independently(44,45). Reverse cholesterol transport trans-
fers cholesterol from the tissues to the liver via HDL,
reducing the risk of cholesterol accumulation and athero-
sclerosis(46). Cholesterol can be efﬂuxed from the tissues
by the receptors ABC-A1, and scavenger receptor class
B member 1, or via receptor independent passive diffu-
sion to nascent HDL(47–49). The incorporated cholesterol
is then esteriﬁed by lecithin-cholesterol acyltransfer-
ase(50). Cholesterol enters the liver either directly, via
the receptor scavenger receptor class B member 1, or
via the enzyme cholesteryl ester transfer protein
(CETP). CETP mediates the 1:1 exchange of cholesterol
from HDL with TAG from VLDL and LDL(51). Once in
the liver, cholesterol can be removed from the body.
Cholesterol excretion
Cholesterol can be removed from the body by two
mechanisms: directly via the hepatic ABCG5/G8
receptor and efﬂuxed to the gall bladder or alternatively,
cholesterol can be converted to bile acids for faecal excre-
tion(52,53). Approximately 98 % of bile acids are conju-
gated to either taurine or glycine, as conjugation
increases polarity, which reduces passive transport from
the intestinal lumen into enterocytes, and allows the
movement of bile acids to be tightly regulated, and
under receptor control; in addition to improving solubil-
ity(54). Removal of the amino acid from conjugated bile
acids, by bacterial bile salt hydrolase (BSH), decreases
reabsorption efﬁciency, thus unconjugated bile acids
make up 98 % of the 5 % of bile acids that are excreted
daily(55,56). This modiﬁcation is of signiﬁcant interest,
as the production of more readily excreted bile acids,
may lead to the increased conversion of cholesterol to
bile acids to replace those lost, in turn lowering serum
cholesterol(57).
Cholesterol and healthspan
Intrinsic ageing
The ageing process has been associated with an increase
in both total cholesterol (TC) and LDL-cholesterol. For
Fig. 4. (Colour online) Modelling overview. (1) Identify the system to model and hypothesis formation. (2) Identify
pre-existing models; using the BioModels Database, a repository for peer reviewed models. (3) If no model of the
system of interest exists: produce a network diagram. If a model does exist: download model and move to step 5,
then step 7. (4) Establish mathematical framework. (5) Identify a suitable modelling tool; there are several available
including: COPASI, which we utilised in our updated model of cholesterol metabolism(123), CellDesigner,
Mathematica and MATLAB. (6) Obtain initial concentrations of species, rate laws and kinetic data to construct the
model. The online resources BRENDA and SABIO-RK provide a substantial volume of kinetic data. (7) Run
simulations. (8) Validate the model. (9) Explore the hypotheses, and determine if the model accurately represents the
biological system, and can be used to make predictions, or if the model needs reﬁning. (10) Conduct further wet
laboratory experiments based upon model output. (11) Code the model in the exchange format, Systems Biology
Markup Language and deposit in the BioModels Database. Adapted from Mc Auley and Mooney(135).
A. E. Morgan et al.4
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instance, Ericsson et al. reported an increase in TC from
4·8 mM/l in the young (aged 20–39 years), to 5·14 mM/l in
the middle aged (aged 40–59 years), and to 5·44 mM/l in
old aged (aged 60–80 years) healthy Scandinavian volun-
teers(58). Furthermore, LDL-cholesterol increased with
age, from 3·37 in the young, to 3·76 in the middle aged
and to 4·05 mM/l in the old aged. Additionally, VLDL-
cholesterol has been observed to either remain steady
or increase with age, while HDL-cholesterol appears to
be unaffected by the ageing process(58,59). Abbott et al.
also found sex inﬂuences the lipoprotein proﬁle. For
example, females exhibited higher levels of LDL-choles-
terol, especially in those using oestrogen hormones, and
increased HDL-cholesterol, whereas VLDL-cholesterol
was greater in males(59). The age-associated dysregula-
tion of cholesterol metabolism, and accumulation of
LDL-cholesterol, has been associated with alterations
to several key mechanisms, including cholesterol absorp-
tion, LDL-cholesterol clearance, bile acid synthesis and
subsequent intestinal bacterial modiﬁcation (Fig. 5)(5).
Intestinal cholesterol absorption varies greatly among indi-
viduals, with estimates ranging from 20·0 to 80·1 %(59,60).
Evidence from murine models suggests cholesterol
absorption increases signiﬁcantly with age(7). Rodent
studies have demonstrated this is mediated by a signiﬁ-
cant increase in NPC1L1 in both the duodenum and
jejunum, while ABCG5/G8 expression is suppressed(61).
It has been estimated this increase in cholesterol absorp-
tion and concurrent reduction in efﬂux from enterocytes,
confers a 19–40 % increase in cholesterol absorption with
age(61). Moreover, it was observed that high levels of oes-
trogen up-regulated NPC1L1 and ABCG5/G8 mRNA
expression. Oestrogen and ageing have been reported to
enhance cholesterol absorption via the estrogen receptor-
α pathway(61). It is important to note that these ﬁndings
have not yet been observed in human individuals(60).
Bile acid metabolism is also affected by the ageing pro-
cess, most signiﬁcantly, there is a reduction in bile acid
synthesis. Wang(7) found ageing resulted in a signiﬁcantly
reduced biliary bile acid output, from 192 to 211 to 124–
157 µM/h per kg in mice. Additionally, Wang(7) demon-
strated intrinsic ageing resulted in a reduction in bile
acid synthesis, with a 33·3–57·1 and 41·7–56·3 % decrease
in cholesterol 7α-hydroxylase (CYP7A1) activity in male
and female mice, respectively, dependent on dietary and
genetic factors. Similarly in human subjects, an inverse
correlation between age and CYP7A1 expression has
been described(62). For instance, cholesterol 7α-hydroxyl-
ation rates were reduced by 50 % for individuals over 65
years, compared with individuals below 65 years of age
in one Italian cohort(63). Bertolotti et al.(63) estimated
by linear regression analysis a 60 mg/d (about 150 µM/
d) decline every 10 years, in cholesterol undergoing chol-
esterol 7α-hydroxylation, while Einarsson et al.(64) esti-
mated an 80 mg/d (200 µM/d) reduction over the same
time period. Bertolotti et al.(62) propose the age-related
reduction in CYP7A1 expression could be related to
the concomitant decline in hepatic nuclear factor four
and co-activator CYP7A1 promoter-binding factor/liver
receptor homologue-1, mediated by the decline in growth
hormone and insulin-like growth factor.
Once bile acids reach the small intestine, modiﬁcation
by digestive microﬂora occurs inﬂuencing enterohepatic
circulation. Many digestive bacteria produce the enzyme
BSH, which deconjugates bile acids, decreasing reabsorp-
tion efﬁciency, and enhancing excretion. For example,
Tanaka et al.(65) reported 59 and 98 % of Lactobacillus
and Biﬁdobacteria strains, isolated from faeces are BSH
positive. With age there are several changes to the gut
microﬂora, including a decline in the number and species
diversity of Lactobacillus and Biﬁdobacterium(8,66).
Therefore, it is possible that the age-related decline of
these bacterial species reduces bile acid deconjugation,
and in turn reduces the conversion of cholesterol to bile
acid. This may play a role in the accumulation of choles-
terol with age(5).
It has also been reported, the clearance rate of LDL-
cholesterol is affected by the ageing process. The apo
B-100 containing lipoproteins, LDL-cholesterol and
VLDL-cholesterol are removed from the blood via hep-
atic LDLr, for elimination, either by direct efﬂux or con-
version to bile acids. Millar et al.(6) determined the mean
LDL apo B-100 residence time was 2·42 d for younger
male adults (mean age 31 (SD 6) years) and 3·46 d for
older male adults (mean age 61 (SD 10) years). With
age, a decline in LDLr activity and/or numbers is
thought to be responsible for the reduction in LDL clear-
ance rate and increase in residence time. The reduced
conversion of cholesterol by CYP7A1 may play a role
in reduction of LDLr. Additionally, proprotein conver-
tase subtilisin/kexin type 9, a proprotein convertase
responsible for the degradation of LDLr has been corre-
lated with age(67). Interestingly, proprotein convertase
subtilisin/kexin type 9 has also been correlated with
BMI, TC, LDL-cholesterol and TAG(68). Furthermore,
Millar et al.(6) observed, that although VLDL apo
B-100 residence time was not affected by age, the produc-
tion rate of VLDL apo B-100 was correlated with age.
The age-related increase in body fat and elevated plasma
free fatty acids were attributed to this increase in VLDL
apo B-100 production rate.
Cholesterol metabolism and diet
Herron et al.(69) examined the effect of about 640 mg/d
cholesterol feeding on men aged 18–57 years, and deter-
mined that 37·5 % of subjects behaved as hyper-respon-
ders, with an increase of ≥0·06 mM/l in TC, while 62·5
% behaved as hypo-responders, with an increase in TC
of <0·05 mM/l. Hyper-responders exhibited a signiﬁcant
23·0, 7·8 and 18·0 % increase in LDL-cholesterol and
HDL-cholesterol and LDL:HDL ratio, respectively,
whereas changes to LDL-cholesterol, HDL-cholesterol,
TG and LDL:HDL ratio were NS for hypo-responders.
Interestingly, hyper-responders exhibited elevated leci-
thin-cholesterol acyltransferase and CETP activity, sug-
gesting the up-regulation of reverse cholesterol
transport as a compensatory mechanism, to reduce the
risk of atherosclerosis. Quintao et al.(70) propose tissue
pools of cholesterol may rapidly expand in response to
cholesterol feeding, even in the absence of aberrations
to plasma cholesterol levels. Typically, there are two
Cholesterol metabolism and ageing 5
Pr
o
ce
ed
in
gs
o
f
th
e
N
ut
ri
ti
o
n
So
ci
et
y
7$$!(  8  "6 
.			
, D: 05" 7$$!DDD 201"86  "62 " /8C"#8$) 57#$" 
 C	0$#%192$$ $701"86 "$"# 5%#0C08:01:0$7$$!DDD 201"86  "62 "$"# 
main mechanisms to compensate for an increase in diet-
ary cholesterol; elevated cholesterol excretion and
decreased cholesterol synthesis. It has been suggested a
reduction in cholesterol intake should be considered
unnecessary for individuals who have already reduced
SFA intake, and increased PUFA:SFA ratio(71).
Edington et al.(71) determined a 2-fold increase or
decrease in dietary cholesterol in participants who also
reduced dietary fat with an increased PUFA:SFA ratio
had no effect on TC or LDL-cholesterol after 8 weeks.
This is due to the signiﬁcant impact SFA had on serum
LDL-cholesterol, by inﬂuencing several regulatory
mechanisms. Firstly, it has been observed there is a
reduction in LDLr; resulting in reduced LDL-cholesterol
clearance and increased LDL-cholesterol(72). Mustad
et al.(72) demonstrated an 8-week reduction in SFA
resulted in a 10·5 % increase in LDLr and subsequent
11·8 % decrease in LDL-cholesterol. It has been esti-
mated for every 1 % increase in LDLr, there is a 0·74
% reduction in LDL-cholesterol. Secondly, SFA may
inﬂuence cholesterol synthesis(73). Glatz and Katan(73)
determined a low PUFA:SFA ratio diet resulted in
increased cholesterol synthesis, compared with a high
PUFA:SFA ratio diet (1·86 v. 1·55 mM/d). Additionally,
Jones et al.(74) demonstrated maize oil increased absolute
cholesterol synthesis from 13·9 mg/kg per d at baseline,
to 21·3 mg/kg per d. Thirdly, it has been demonstrated
SFA inﬂuences the concentration of CETP. For example,
Jansen et al.(75) observed that CETP concentrations were
signiﬁcantly elevated by 12 and 11 %, in individuals on a
high SFA diet, compared with individuals on the
National Cholesterol Education Program StepI diet
and MUFA diet, respectively. Additionally, an elevation
of SFA from 8·4 to 11 % decreased lecithin-cholesterol
acyltransferase activity from 56 to 74 nM/ml per h,
which may result in decreased reverse cholesterol trans-
port and inﬂuence CVD risk(76).
Cholesterol metabolism and disease
The age-related accumulation of both TC and LDL-
cholesterol has been associated with the pathogenesis of
several diseases(77–79). In a meta-analysis of sixty-two
studies, a 17·5 % reduction in relative risk for all-cause
mortality for every 1 mM/l decrease in TC was reported,
while each 1 mM/l decrease in LDL-cholesterol was asso-
ciated with a 15·6 % relative risk reduction for all-cause
mortality(4).
CHD has been associated with signiﬁcantly elevated
TC, LDL-cholesterol, TAG, apo B and Lp(a) and
reduced HDL-cholesterol and apo A–I in both
American males and females(79). Gould et al.(4) reported
a 24·5 and 29·5 % reduction in relative risk for CHD-
related mortality and CHD event respectively for every
1 mM/l decline in TC. Additionally, each 1 mM/l decline
in LDL-cholesterol was associated with a 28·0 and
26·6 % decline in relative risk for CHD-related mortality
and CHD event, respectively. Sharrett et al.(79) found
that each 1 mM/l increase in LDL-cholesterol was asso-
ciated with a relative risk for CHD of between 1·36
and 1·44 for males and 1·19 and 1·32 for females, while
a 0·4 mM/l increase in HDL-cholesterol was associated
with a 0·64–0·72 and 0·64–0·76 relative risk for CHD
for males and females, respectively. Interestingly, the
Fig. 5. (Colour online) Overview of age-related changes to cholesterol metabolism.
A. E. Morgan et al.6
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decreased risk for mortality with reduced TC has been
observed to decline with age. For example, a meta-
analysis conducted by Lewington et al.(80) concluded a
1 mM/l reduction in TC was associated with an about
50 % reduction in IHD mortality for 40–49 year olds,
which decreased to an about 33 % reduction for 50–69
year olds and about 17 % for 70–89 year olds.
Intriguingly, several studies have described an inverse
relationship between cholesterol and mortality(81). Lv
et al.(82) observed a 19 % decrease in relative risk for
each 1 mM/l increase in LDL-cholesterol in Chinese
≥80 year olds. Additionally, a 40 % lower risk for mor-
tality was associated with those with abnormally high
LDL-cholesterol (≥3·37 mM/l), compared with those
with a lower plasma concentration of LDL-cholesterol.
Similarly, Takata et al.(83) observed a 0·8 % decrease in
mortality for each 1 mg/dl (0·026 mM/l) increase in
LDL-cholesterol in Japanese ≥80 year olds. In addition,
each 1 mg/dl increase in TC was associated with a 0·9 %
reduction in mortality.
Targeting cholesterol metabolism as a therapeutic
strategy
There are many strategies utilised in the treatment of
hypercholesterolaemia. These can be used singularly or
in combination, and include pharmacological interven-
tion, changes to diet and exercise regimens, and dietary
supplementation(9,11,84,85).
Pharmacological intervention
Lipid-lowering drugs are often utilised in the treatment
of CVD (Fig. 6). Statins are often recommended for
those diagnosed with CVD, or those with a high risk of
developing the disease, due to their tolerability and
efﬁcacy(86). Statins act by competitively inhibiting
HMG CoA reductase, the rate-limiting enzyme of chol-
esterol synthesis in order to lower serum cholesterol,
thus reducing CVD risk(87). Simivastatin reduced LDL-
cholesterol by 33 % after 12 weeks, in patients with a
history of myocardial infarction, while atorvastatin
exhibited a 49 % reduction(88). A meta-analysis of four
trials demonstrated standard-dose statin therapy reduced
LDL-cholesterol by 22 %, to a mean of 2·59 mM/l (101
mg/dl), while high-dose statin therapy reduced LDL-
cholesterol by 42 %, to a mean of 1·92 mM/l (75 mg/
dl)(89). The standard-dose therapy was associated with
a coronary death or myocardial event rate of 9·4 %,
whereas high-dose therapy was associated with an 8·0
% event rate. Signiﬁcantly, overall statin therapy resulted
in a 16 % odds reduction in coronary death or myocar-
dial infarction(89). Ridker et al.(90) observed that patients
whose statin therapy reduced LDL-cholesterol to <70
mg/dl (<1·81 mM/dl), had a reduced rate of recurrent
myocardial infarction or death from coronary events
(2·7 events per 100 person-years), than individuals
whose statin therapy did not reach this goal (4·0 events
per 100 person-years). However, it has also been demon-
strated non-statin therapy (diet, bile acid sequesterants
and ileal bypass surgery) reduced CHD risk equally to
that of statins, with each 1 % reduction in LDL-
cholesterol corresponding to a 1 % decrease in CHD
risk(10). Statins can also be used in combination with
drugs such as Ezetimbibe, which targets NPC1L1 to
lower cholesterol absorption. Cannon et al.(84) observed
that combination therapy lowered LDL-cholesterol by
a further 24 % than statin therapy alone. Combination
therapy also signiﬁcantly reduced myocardial infarction
and ischaemic stroke risk.
Dietary intervention
A reduced intake of SFA and an increase in MUFA and
PUFA may be useful in maintaining a healthy lipid
proﬁle, and reducing CHD risk(11). An 8-week reduction
in SFA was observed to reduce TC and LDL-cholesterol
by 9·3 and 11·8 %, respectively, in healthy males
and females aged between 20 and 65 years(72).
Additionally, Berry et al.(91) reported a 12-week
MUFA or PUFA diet reduced TC by about 10 and
16 %, respectively, while reducing LDL-cholesterol by
14 and 21 %. A meta-analysis of 13 614 participants par-
ticipating in diets where SFA was replaced with PUFA,
found that on average there was a 0·76 mM/l (29 mg/dl)
reduction in TC, and that each 1 mM/l reduction in TC
was associated with 24 % reduced risk for a CHD
event. Moreover, each additional year of diet was related
to a further 9·2 % risk reduction(11).
Additionally, the use of phytosterols is recommended
as a therapeutic strategy for the treatment of hyperchol-
esterolaemia. It is estimated a 2 g/d dose of phytosterols
lowers LDL-cholesterol by 10 %(92). A meta-analysis
of 124 studies concluded 0·6–3·3 g/d phytosterols
reduced LDL-cholesterol by 6–12 %, with stanols and
sterols showing similar LDL-cholesterol lowering
efﬁcacies(85). The effect of phytosterols diminishes
above about 2–3 g/d(92), consequently 2 g/d is generally
accepted as the daily amount required to help treat
hypercholesterolaemia(93).
Furthermore, meta-analysis of sixty-seven trials
revealed that soluble ﬁbre could lower TC and LDL-
cholesterol by 0·045 and 0·057 mM/l per g soluble ﬁbre,
respectively(94). There are a variety of mechanisms that
dietary ﬁbre could inﬂuence; for example, bile acid
micelle formulation, fat excretion, intestinal motility,
SCFA production and absorption of macronutri-
ents(95–97). Interestingly, diet may not only impact choles-
terol metabolism directly, and may also interact with the
gut microbiome(98). For example, David et al.(99) describe
that short-term changes to diet could signiﬁcantly inﬂu-
ence both the microbial community structure and bacter-
ial gene expression. For instance, a 5 d animal-based-diet
signiﬁcantly altered the abundance of twenty-two
clusters, elevated faecal bile acid concentration, and
increased BSH expression(99). Everard et al.(100) describe
that high-fat feeding signiﬁcantly affected twenty genera.
This may have been inﬂuenced by a decline in the
antimicrobial peptide regenerating islet-derived protein
three gamma. Interestingly, prebiotic treatment increased
regenerating islet-derived protein three gamma about
Cholesterol metabolism and ageing 7
Pr
o
ce
ed
in
gs
o
f
th
e
N
ut
ri
ti
o
n
So
ci
et
y
7$$!(  8  "6 
.			
, D: 05" 7$$!DDD 201"86  "62 " /8C"#8$) 57#$" 
 C	0$#%192$$ $701"86 "$"# 5%#0C08:01:0$7$$!DDD 201"86  "62 "$"# 
6-fold within the colon. Targeting the digestive microbiota
with pre- and probiotics is a potential avenue for the treat-
ment of diseases including hypercholesterolaemia.
Targeting the gut microbiome
There is emerging evidence indicating the important role
for the gut microbiome in regulating many biological sys-
tems, including cholesterol metabolism(101,102). Ageing is
associated with the alteration of the gut microbiome.
These changes differ between individuals and popula-
tions, as diet, lifestyle, host health and antibiotic use
likely play a role in composition(103,104). However, it
has been observed Lactobacillus and Biﬁdobacterium spe-
cies diversity and total count decline with age(8,66).
Supplementation with probiotics may have the ability
to partially ameliorate changes associated with ageing,
such as immunosenescence, neurodegeneration, carcino-
genic transformation and hypercholesterolaemia(105,106).
With regard to hypercholesterolaemia treatment, sup-
plementation with probiotics has been associated with a
decline in TC and LDL-cholesterol(9). A meta-analysis
of probiotic administration studies concluded probiotic
administration resulted in a mean 6·40 mg/dl (0·17 mM/l)
reduction in TC and 4·90 mg/dl (0·13 mM/l) reduction in
LDL-cholesterol. Additionally, probiotics were observed
to have beneﬁcial effects on TC and LDL-cholesterol for
individuals with high, borderline high and normal choles-
terol levels(9). Probiotics have also been an effective treat-
ment strategy for individuals with underlying conditions.
For example, Bernini et al.(107) observed ingestion of
80 ml probiotic milk containing 3·4× 108 colony-forming
units/ml Biﬁdobacterium lactis HN019 for 45 d, signiﬁ-
cantly lowered TC from 209 to 194 mg/dl (5·40 and
5·02 mM/l), and LDL from 128·5 to 111 mg/dl (3·32–
2·87 mM/l) in patients with metabolic syndrome, in add-
ition to lowering BMI. Moreover, the proinﬂammatory
cytokines TNF-α and IL-6 were signiﬁcantly reduced
with probiotic treatment.
There are several proposed mechanisms to explain the
lipid-lowering ability of probiotics(108). For example,
some probiotics produce the bile acid deconjugating
enzyme BSH, which may increase bile acid excretion,
and up-regulate the conversion of cholesterol to bile
acids to replace those lost(109). It has also been observed
that probiotics increase SCFA, which inhibit the hepatic
rate-limiting enzyme in cholesterol synthesis, HMG CoA
reductase(108). Furthermore, there may be a reduction in
cholesterol absorption due to the assimilation and pos-
sible incorporation of cholesterol into the bacterial cell
membrane(110). Additionally, some bacteria may act by
destabilising cholesterol micelles resulting in the
coprecipitation of cholesterol with deconjugated bile
acids(110).
Applying systems biology to our understanding of
cholesterol metabolism and ageing
It is apparent from our discussion of cholesterol metabol-
ism, that it is an exceptionally complex system with a
multitude of interacting mechanisms(111,112). Many of
these mechanisms interact via positive and negative feed-
back regulators, the dynamics of which is not trivial. Our
understanding of this complexity is further compounded
by ageing which alters the behaviour of these regulatory
mechanisms, thus modifying the overall dynamics of
whole-body cholesterol metabolism. Moreover, changes
to extrinsic factors such as diet exert a signiﬁcant inﬂu-
ence on the overall behaviour of this system. Thus, it is
imperative if we are to gain a more in-depth appreciation
of cholesterol metabolism and its interaction with ageing,
that we investigate this system in a more integrated man-
ner. The systems biology paradigm contrasts with the
more traditional reductionist approach, commonly used
in nutrition research, and offers a more integrated way
to study this multifaceted system(14,113,114). A funda-
mental element of this paradigm shift is the close coup-
ling of computational modelling with experimental
Fig. 6. (Colour online) UK prescription drugs for CVD. Data from British Heart Foundation(134).
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work(115–118). Our group has used computational systems
biology to investigate cholesterol metabolism and age-
ing(119). Firstly, we constructed a whole-body model of
cholesterol metabolism(120,121). The model is deﬁned by
the key components that characterise whole-body choles-
terol balance, namely cholesterol ingestion, excretion and
synthesis together with LDLr turnover and reverse chol-
esterol transport. Using in silico experiments we explored
the impact of ageing on these fundamental elements of
cholesterol metabolism. We investigated the inﬂuence
of ageing on cholesterol absorption and it was found
that for every 10 % increment in the rate of cholesterol
absorption, there was a concomitant increase of 12·5
mg/dl in LDL-cholesterol. The model also revealed that
increasing cholesterol absorption from 50 to 80 % by
age 65 years, resulted in a 34 mg/dl increase in plasma
LDL-cholesterol. In addition, the model found that redu-
cing the number of hepatic LDLr had a signiﬁcant
impact on the system. An increase of 116 mg/dl in
LDL-cholesterol was observed by 65 years in response
to a reduction of 50 % in their numbers; thus emphasis-
ing LDLr maintenance as a key component in maintain-
ing cholesterol metabolism during ageing. This model is
coded in the Systems Biology Markup Language and
archived in the BioModels Database, a repository for
models encased in Systems Biology Markup Language
exchange framework (http://www.ebi.ac.uk/biomodels-
main/BIOMD0000000434). This means the model is
straightforward to update and adapt, a feature exploited
by other groups working in this area(122). We recently
implemented signiﬁcant updates to the model described
earlier for the following reasons(123). The model was lack-
ing several key mechanisms which recent experimental
evidence has stressed are central to the regulation of chol-
esterol metabolism. Brieﬂy, these processes included
plasma membrane receptors, and in vivo and intestinal
microﬂoral enzymes. Therefore, it was deemed cogent
that these ninety-six additional mechanisms were incor-
porated into the original model(5). We found that our
updated model behaved as a hypo-responder to excessive
cholesterol feeding. Moreover, the model was utilised to
investigate the effects of ageing coupled with three differ-
ent CETP genotypes. Ageing in the presence of a geno-
type conferring low CETP activity resulted in a 0·6 %
decrease in LDL-cholesterol after 1000 h. In comparison,
ageing with a genotype indicative of high CETP activity,
provoked a 1·6 % increase in LDL-cholesterol levels
(Fig. 7). Thus, our new model consolidates experimental
ﬁndings, which emphasise the signiﬁcance of CETP
genotypes in healthspan(123).
Complementing computational models with simulated
digestive tracts
To complement our in silico studies of cholesterol metab-
olism, we aim to develop a simulator of the human
digestive tract. The digestive track simulator will be
used to reﬁne and inform our computational model.
One example is the simulator of the human intestinal
microbial ecosystem reactor, which represents the length
of the human digestive system, with several closed reac-
tors used to represent the differing conditions (microbial
ecosystem, pH, enzymes, etc.) of each section of the
digestive tract(124). The ﬂexible nature of the simulator
of the human intestinal microbial ecosystem reactor
means that it can be easily adapted. This may include
additional reactors to more accurately represent the
human digestive tract(125,126). Simulated digestive tracts,
such as the simulator of the human intestinal microbial
ecosystem reactor provide a suitable test environment
to supplement experimental data on potential therapeutic
strategies. For example, De Smet et al.(127) determined
administration of Lactobacillus to pigs for 4 weeks
decreased TC and LDL-cholesterol by 15 and 24 %,
respectively. Additionally, TC and LDL-cholesterol
reduced a further 18 and 34 % 3 weeks after treatment.
Follow-up experimentation using the simulator of the
human intestinal microbial ecosystem reactor was able
to provide details of the intestinal bacterial population
and overall metabolic activity associated with this treat-
ment(125). Recently, a continuous gut adhesion model
was developed using mucin-alginate beads to immobilise
bacteria, which may more effectively represent the gut
lining and intestinal lumen. This system was also used
to examine bacterial colonisation following probiotic
treatment(128). The TNO gastrointestinal model can be
used to examine compound absorption(129). This model
simulates ingestion of food and water, digestive enzyme
and bile salt release, peristalsis, body temperature, and
transit through the stomach and small intestine (TNO
gastrointestinal model-1) and large intestine (TNO
gastrointestinal model-2) under computer control. The
model can be altered to represent a different species,
such as a human or pig, or can represent varying age,
such as infant, adult and older people(129). This is par-
ticularly signiﬁcant for the augmentation and reﬁnement
of our computational model. It is hoped that utilising
both these approaches in tandem will help to signiﬁcantly
deepen our understanding of cholesterol metabolism and
its relationship with ageing.
Conclusions
We have outlined how the age-related dysregulation of
cholesterol metabolism is inﬂuenced by many factors.
Speciﬁcally, (i) an increase in LDL-cholesterol residence
time due to reduction in LDLr and concomitant decline
in LDL-cholesterol clearance;, (ii) a decline in CYP7AI
activity which reduces bile acid synthesis, one pathway
for cholesterol removal; (iii) a reduction in digestive bac-
teria which modify bile acids that reduce reabsorption
and promotes excretion; (iv) a potential increase in chol-
esterol absorption due to an increase in NPC1L1 and
decrease in ABCG5/G8, as observed in murine models.
Cholesterol metabolism is also inﬂuenced by diet and
gut microbial dynamics, therefore studying the mechan-
isms underpinning these complex interactions is challen-
ging. Due to its ability to handle this complexity
computational modelling has been used to study the
intricacies associated with ageing and cholesterol
Cholesterol metabolism and ageing 9
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metabolism. Computational modelling is a key compo-
nent of the systems biology paradigm which nutrition
research is beginning to adopt. It is possible nutrition
research will beneﬁt signiﬁcantly from this approach in
the coming years. For instance, computational modelling
will be needed to deepen our understanding of the role
the gut microbiome has to play in host health(130). In tan-
dem with computational modelling, experimental
approaches are a key part of systems biology. An import-
ant experimental method which dovetails with computa-
tional modelling is the use of artiﬁcial digestive tracts.
These can be used to simulate the activities of the digest-
ive tract under a wide variety of conditions, something
which is difﬁcult to achieve in vivo(131). Thus, utilising
these methodologies as part of a systems biology frame-
work, provides a means of investigating the dynamics of
the gut microbiome together with its interaction with
cholesterol metabolism and ageing. In order for this
approach to be successful it is imperative for nutritionists
to work closely with scientists from the systems biology
community. This novel way of conducting nutrition
research will in turn facilitate the discovery of nutrient-
based strategies to treat hypercholesterolaemia, which
so often accompanies the ageing process.
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